Olema Oncology Appoints Jason O'Byrne as CFO Ahead of Pivotal OPERA-01 Data
核心洞察
Olema Oncology has appointed Jason O'Byrne, MBA, as Chief Financial Officer as the company approaches pivotal data from its OPERA-01 study and a potential first commercial launch.
O'Byrne joins from Vir Biotechnology, where he served as Executive Vice President and CFO, and previously held CFO roles at Caribou Biosciences and Audentes Therapeutics (搜索).
His background spans corporate strategy, capital markets, business development, and financial management, including leadership of Caribou's IPO and the $3 billion Astellas acquisition of Audentes.
Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer (搜索) and beyond, announced the appointment of Jason O'Byrne, MBA, as Chief Financial Officer. The appointment comes as the company approaches pivotal data from its OPERA-01 study and prepares for a potential first commercial launch.
"We are very pleased to welcome Jason to Olema at an important time for the Company," said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. "As we approach pivotal data from OPERA-01 and prepare for our first potential commercial launch, the breadth and depth of Jason's expertise in corporate strategy, capital markets, business development, and financial management and operations will be essential as we continue Olema's transformation into a fully integrated oncology company."
Executive Leadership and Financial Expertise
Mr. O'Byrne brings more than two decades of finance and global operations leadership across high-growth biotechnology and pharmaceutical organizations. He joins Olema from Vir Biotechnology, where he served as Executive Vice President and Chief Financial Officer, leading the Finance, Investor Relations, and Information Technology functions.
Previously, Mr. O'Byrne was Chief Financial Officer of Caribou Biosciences. Across both organizations, he led a wide range of financial and capital markets initiatives, including Caribou's initial public offering. Prior to Caribou, he served as Senior Vice President of Finance at Audentes Therapeutics (搜索), where he oversaw financial due diligence and integration for its $3 billion acquisition by Astellas Pharma. Earlier in his career, Mr. O'Byrne spent over a decade at Genentech and Roche in finance leadership roles of increasing responsibility, spanning clinical development, commercial, and global operations.
Mr. O'Byrne holds an MBA in Finance, with distinction, from New York University's Stern School of Business and a Bachelor of Applied Science in Mechanical Engineering from the University of British Columbia.
Pipeline and Strategic Outlook
"I am thrilled to join Olema at such an exciting stage in its evolution and believe palazestrant and OP-3136 have the potential to meaningfully improve the lives of people living with breast cancer (搜索) and beyond," said Mr. O'Byrne. "With a strong balance sheet and a series of important milestones ahead, I look forward to working with Sean and the executive team to help scale Olema through this next chapter and deliver durable benefit to patients and long-term value to shareholders."
Olema Oncology is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (搜索) antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6 (搜索)) inhibitor, now in a Phase 1 clinical study.
Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts.